-
REGENXBIO completes dosing in Duchenne gene therapy confirmation study; planning BLA submission to FDA in Q3 2026
REGENXBIO has completed dosing in the confirmatory study of RGX-202, an AAV-delivered microdystrophin gene therapy
-
Life with Lily: My Favorite Accessible Fashion & Beauty Tips
Hello! In this blog, I’m sharing accessible beauty and fashion tips I’ve collected through plenty








